nilvadipine nilvadipine nilvadipine is a calcium channel blocker (ccb) used for the treatment of hypertension and chronic major cerebral artery occlusion. nilvadipineclinical dataahfs/drugs.cominternational drug namesatc codec08ca10 (who) identifiers iupac name 3-methyl 5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate cas number75530-68-6 ypubchem cid4494drugbankdb06712 ychemspider4338 nunii0214fut37jkeggd01908 ychemblchembl517427 ncomptox dashboard (epa)dtxsid2046624 echa infocard100.232.871 chemical and physical dataformulac19h19n3o6molar mass385.376 g·mol−13d model (jsmol)interactive image smiles cc1=c(c(c(=c(n1)c#n)c(=o)oc)c2=cc(=cc=c2)(=o))c(=o)oc(c)c inchi inchi=1s/c19h19n3o6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21h,1-4h3 nkey:faiifdpaeukbep-uhfffaoysa-n n ny (what is this?) (verify) pathohistochemical studies have revealed that the volume of the infarction in the middle cerebral artery occlusion model could be decreased by nilvadipine. experimental research nilvadipine was tested in clinical trial as a possible treatment for alzheimer's disease in ireland by the roskamp institute, florida, usa and trinity college, ireland. following this study, an international research consortium led by trinity college dublin (ireland) in may 2011 announced the selection for funding of a large-scale european clinical trial of nilvadipine. more than 500 alzheimer's disease patients will participate in the multicenter phase iii clinical trial designed to study the effectiveness of nilvadipine.